Skip to main
EXEL
EXEL logo

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 26%
Hold 42%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis Inc. maintains a strong outlook due to the continued success of its flagship product, cabozantinib, particularly in renal cell carcinoma (RCC) and neuroendocrine tumors (NETs), bolstered by recent label expansions and strong clinical trial data. The promising performance of zanzalintinib in combination with atezolizumab, which shows a statistically significant improvement in overall survival compared to existing treatments, further enhances the company's growth potential. Additionally, the positive trajectory for zanzalintinib indicates that Exelixis may effectively broaden its portfolio beyond cabozantinib, positioning itself for increased market presence and revenue generation.

Bears say

Exelixis Inc. faces a significant financial challenge due to an anticipated patent cliff in 2031, with projections indicating an 80% revenue decline by 2032, which exceeds the Street's forecast of 68%. Revenue erosion is expected to result from generic entries, where drugs typically lose an average of 54% in their first year after such entries and 97% by the seventh year. Additionally, competitive risks and regulatory uncertainties related to their key product cabozantinib, as well as ongoing developmental risks for their pipeline candidates, contribute to a cautious outlook on the firm’s long-term financial performance.

Exelixis (EXEL) has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 26% recommend Buy, 42% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 19 analysts, Exelixis (EXEL) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.